Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Mar 8:20:51-53.
doi: 10.1016/j.gore.2017.03.002. eCollection 2017 May.

A recurrent endometrial stromal sarcoma harbors the novel fusion JAZF1-BCORL1

Allison J Allen  1 , Siraj M Ali  2 , Kyle Gowen  2 , Julia A Elvin  2 , Tanja Pejovic  1
Affiliations
Case Reports

A recurrent endometrial stromal sarcoma harbors the novel fusion JAZF1-BCORL1

Allison J Allen et al. Gynecol Oncol Rep. .

Abstract

•Genomic alterations may improve diagnostic certainty and subsequent treatment of endometrial stromal sarcoma.•Novel JAZF1-BCORL1 mutation was identified.•Targeted therapeutics to down-stream targets may improve survival benefit in these patients.

Keywords: Chromatin; Endometrial stromal sarcoma; JAZF1; Polycomb.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Recurrent endometrial stromal sarcoma harbors the novel JAZF1-BCORL1 fusion. A–C) Photomicrographs of recurrent tumor at 100 × demonstrating LG-ESS. D) JAZF1-BCORL1 genomic rearrangement.
See this image and copyright information in PMC

References

    1. Chan J.K. Endometrial stromal sarcoma: a population-based analysis. Br. J. Cancer. 2008;99:1210–1215. - PMC - PubMed
    1. Chiang S. Frequency of known gene rearrangements in endometrial stromal tumors. Am. J. Surg. Pathol. 2011;35:1364–1372. - PubMed
    1. Conklin C.M.J., Longacre T.A. Endometrial stromal tumors: the new WHO classification. Adv. Anat. Pathol. 2014;21:383–393. - PubMed
    1. Dahhan T., Fons G., Buist M.R., Ten Kate F.J.W., van der Velden J. The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2009;144:80–84. - PubMed
    1. De Raedt T. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014;514:247–251. - PubMed

Publication types